Takeda Oncology
Iain Morgan is an experienced leader in oncology marketing and operations, currently serving as the Head of Oncology Marketing & Operations for UK at Takeda Oncology since November 2020, previously holding the role of Head of Oncology Marketing for the UK. Morgan has an extensive background with Roche from March 2002 to September 2020, where roles included Head of Franchise Marketing & Country Sales Leader for the Haematology Franchise and Senior Brand Manager positions. Earlier career experiences span various roles in sales and account management at Schering-Plough Ltd, AstraZeneca, and experience in the restaurant industry with Pizza Hut and Beefeater Restaurants. Iain Morgan holds an M.B.A. from Henley Business School and has received additional education from Cranfield School of Management and INSEAD.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.